Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 39.6% from a year ago
Cash & equivalents stood at $8.36M at the end of Q1 FY2026, down 39.6% from a year earlier and down 1.4% from the prior quarter. Over 3 fiscal years it compounded at -55.0% a year.
Context
- Cash & equivalents amounted to 41.8% of total assets at the end of Q1 FY2026, up 19.5 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -39.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 8.48M USD
- Year-over-year change
- -66.1%
- 4-year CAGR
- -46.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.48M | -66.1% |
| FY2024 | 2024-12-31 | 25.03M | -3.1% |
| FY2023 | 2023-12-31 | 25.84M | -72.2% |
| FY2022 | 2022-12-31 | 92.94M | -12.4% |
| FY2021 | 2021-12-31 | 106.08M | — |
Cash & Equivalents vs competitors
How ATRA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -39.6% is the 8th highest of 11, against a peer median of -34.8%.
- Cash & equivalents amounts to 41.8% of total assets for ATRA, versus a peer median of 30.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M USD | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $90.42M USD | +48.5% | +4.6% | 88.5% | |
| Mar 2026 | $73.68M USD | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $54.53M USD | -39.0% | +23.0% | 92.6% | |
| Mar 2026 | $50.72M USD | +42.8% | +99.1% | 95.2% | |
| Mar 2026 | €15.01M EUR | -68.3% | -0.5% | 30.7% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Mar 2026 | $8.36M USD | -39.6% | -55.0% | 41.8% | |
| Jan 2026 | $7.13M USD | +122.6% | +2.8% | 25.1% | |
| Mar 2026 | $5.94M USD | -39.6% | -34.3% | 27.4% | |
| Peer median (excluding ATRA) | — | -34.8% | +3.6% | 30.6% | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 106.08M | 92.94M | 25.84M | 25.03M | 8.48M |
| Short-term Investments | 264.98M | 149.88M | 25.88M | 17.47M | 0 |
| Net Receivables | 986K | 40.22M | 34.11M | 1.48M | 1.25M |
| Inventory | 0 | 1.59M | 9.71M | 10.66M | 0 |
| Other Current Assets | 194K | 10.45M | 6.33M | 10.26M | 2.48M |
| Total Current Assets | 384.62M | 295.08M | 101.87M | 64.89M | 12.21M |
| Property, Plant & Equipment (Net) | 79.94M | 74.32M | 58.79M | 41.1M | 7.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.57M | 7.02M | 4.84M | 3.1M | 886K |
| Total Non-current Assets | 83.51M | 81.34M | 63.64M | 44.2M | 8.02M |
| Total Assets | 468.13M | 376.42M | 165.5M | 109.1M | 20.24M |
| Account Payables | 17.37M | 6.87M | 3.68M | 4.37M | 127K |
| Short-term Debt | 0 | 0 | 0 | 0 | 10.78M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 40.76M | 8M | 77.83M | 95.09M | 716K |
| Other Current Liabilities | 25.15M | 32.75M | 37.01M | 6.59M | 2.03M |
| Total Current Liabilities | 105.79M | 78.92M | 142.23M | 134.57M | 14.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 32.67M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 55.71M | 77M | 37.56M | 0 | 0 |
| Other Non-current Liabilities | 1.5M | 35.8M | 39.25M | 41.89M | 1.8M |
| Total Non-current Liabilities | 82.73M | 170.86M | 122.51M | 71.81M | 43.82M |
| Total Liabilities | 188.51M | 249.78M | 264.74M | 206.38M | 58.74M |
| Common Stock | 9K | 10K | 11K | 1K | 1K |
| Retained Earnings | (1.46B) | (1.69B) | (1.97B) | (2.05B) | (2.02B) |
| Accumulated OCI | (368K) | (2.07M) | (204K) | 8K | 1K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 279.61M | 126.64M | (99.23M) | (97.28M) | (38.5M) |
| Total Debt | 28.27M | 71.7M | 57.87M | 43.83M | 52.8M |
| Net Debt | (77.81M) | (21.24M) | 32.03M | 18.8M | 44.32M |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.